Multicentric Castleman Disease (MCD) Clinical Trials

Find Multicentric Castleman Disease (MCD) Clinical Trials Near You

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Tiral of Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection (VDJ001) in the Treatment of Idiopathic Multicentric Castleman Disease (iMCD)

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years, regardless of gender;

• Biopsy or central pathological examination confirmed measurable, symptomatic iMCD (diagnosed according to the guideline for the diagnosis and treatment of Castleman disease in China (2025 )), with the patient presenting at least one of the following symptoms: fatigue, anorexia, fever, or weight loss;

• Clinical laboratory values within 4 weeks prior to the first dose meeting the following criteria:

‣ Absolute neutrophil count (ANC) ≥1.0×10⁹/L;

⁃ Platelet count (PLT) ≥75×10⁹/L;

⁃ Alanine aminotransferase (ALT) \<2.5×ULN;

⁃ Total bilirubin (TBIL) \<2.5×ULN;

⁃ Serum creatinine (SCr) ≤3.0 mg/dL (265 μmol/L).

• ECOG-PS performance status score of 0, 1, or 2;

• If corticosteroids are used (e.g., prednisone), the dose should not exceed 1 mg/kg/day (or equivalent dose of other corticosteroids, see appendix), and must have been stable or reduced within 4 weeks prior to the first dose;

• Patients of childbearing potential (male and female) must agree to use effective contraception during the trial and for 6 months after the last dose; males must not donate sperm and females must not donate oocyte during this period;

• The patient (or their legal guardian or impartial witness) must sign the informed consent form before any study-specific procedures are performed, indicating understanding of the study purpose and required procedures, and voluntary participation in the study.

Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Suncy0618@163.Com
NOT_YET_RECRUITING
Chengdu
The First Affiliated Hospital of Zhejiang University School of Medicine
NOT_YET_RECRUITING
Hangzhou
The Second Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING
Nanchang
Jiangsu Province Hospital
NOT_YET_RECRUITING
Nanjing
Shanxi Bethune Hospital
NOT_YET_RECRUITING
Taiyuan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING
Wuhan
Xiamen Branch,Zhongshan hospital,Fudan University
NOT_YET_RECRUITING
Xiamen
Time Frame
Start Date: 2025-01-27
Estimated Completion Date: 2027-06-30
Participants
Target number of participants: 45
Treatments
Experimental: Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
Placebo_comparator: Placebo
Sponsors
Leads: Beijing VDJBio Co., LTD.

This content was sourced from clinicaltrials.gov